ARS Pharmaceuticals, Inc. Operating Income
ARS Pharmaceuticals, Inc. (SPRY) reported Operating Income of -$61.47 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-13.
Financial Statements › Income Statement
us-gaap:OperatingIncomeLoss · last filed 2026-08-13
- ARS Pharmaceuticals, Inc. operating income (loss) for the quarter ending 2026-06-30 was -$61.47M.
- ARS Pharmaceuticals, Inc. operating income (loss) for the quarter ending 2026-03-31 was -$60.15M.
- ARS Pharmaceuticals, Inc. operating income (loss) for the quarter ending 2025-12-31 was -$41.47M, a 187.86% decline year-over-year.
- ARS Pharmaceuticals, Inc. operating income (loss) for the quarter ending 2025-09-30 was -$53.19M.
- ARS Pharmaceuticals, Inc. operating income (loss) for fiscal 2025 was -$179.45M.
- ARS Pharmaceuticals, Inc. operating income (loss) for fiscal 2024 was -$3.08M.
- ARS Pharmaceuticals, Inc. operating income (loss) for fiscal 2023 was -$67.52M.
- ARS Pharmaceuticals, Inc. operating income (loss) for fiscal 2022 was -$35.52M.
| Period end | Operating Income (Loss) 3 month | Operating Income (Loss) 3 month as first filed | Operating Income (Loss) 6 month | Operating Income (Loss) 6 month as first filed | Operating Income (Loss) 9 month | Operating Income (Loss) 9 month as first filed | Operating Income (Loss) 12 month | Operating Income (Loss) 12 month as first filed |
|---|---|---|---|---|---|---|---|---|
| 2026-06-30 | -$61.47M 10-Q · filed 2026-08-13 | -$121.61M 10-Q · filed 2026-08-13 | -$163.07M derived: sum of 3 quarters · filed 2026-08-13 | -$216.27M derived: sum of 4 quarters · filed 2026-08-13 | ||||
| 2026-03-31 | -$60.15M 10-Q · filed 2026-05-15 | -$101.61M derived: sum of 2 quarters · filed 2026-05-15 | -$154.80M derived: sum of 3 quarters · filed 2026-05-15 | -$202.42M derived: sum of 4 quarters · filed 2026-08-13 | ||||
| 2025-12-31 | -$41.47M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-09 | -$94.66M derived: sum of 2 quarters · filed 2026-03-09 | -$142.27M derived: sum of 3 quarters · filed 2026-08-13 | -$179.45M 10-K · filed 2026-03-09 | ||||
| 2025-09-30 | -$53.19M 10-Q · filed 2025-11-10 | -$100.81M derived: sum of 2 quarters · filed 2026-08-13 | -$137.98M 10-Q · filed 2025-11-10 | -$90.79M derived: sum of 4 quarters · filed 2026-08-13 | ||||
| 2025-06-30 | -$47.61M 10-Q · filed 2026-08-13 | -$84.79M 10-Q · filed 2026-08-13 | -$37.59M derived: sum of 3 quarters · filed 2026-08-13 | -$59.34M derived: sum of 4 quarters · filed 2026-08-13 | ||||
| 2025-03-31 | -$37.18M 10-Q · filed 2026-05-15 | $10.02M derived: sum of 2 quarters · filed 2026-05-15 | -$11.73M derived: sum of 3 quarters · filed 2026-05-15 | -$27.07M derived: sum of 4 quarters · filed 2026-05-15 | ||||
| 2024-12-31 | $47.20M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-09 | $25.45M derived: sum of 2 quarters · filed 2026-03-09 | $10.11M derived: sum of 3 quarters · filed 2026-03-09 | -$3.08M 10-K · filed 2026-03-09 | ||||
| 2024-09-30 | -$21.75M 10-Q · filed 2025-11-10 | -$37.09M derived: sum of 2 quarters · filed 2025-11-10 | -$50.28M 10-Q · filed 2025-11-10 | -$60.51M derived: sum of 4 quarters · filed 2025-11-10 | ||||
| 2024-06-30 | -$15.34M 10-Q · filed 2025-08-13 | -$28.53M 10-Q · filed 2025-08-13 | -$38.76M derived: sum of 3 quarters · filed 2025-08-13 | -$56.74M derived: sum of 4 quarters · filed 2025-08-13 | ||||
| 2024-03-31 | -$13.19M 10-Q · filed 2025-05-14 | -$23.42M derived: sum of 2 quarters · filed 2025-05-14 | -$41.40M derived: sum of 3 quarters · filed 2025-05-14 | -$62.00M derived: sum of 4 quarters · filed 2025-05-14 | ||||
| 2023-12-31 | -$10.23M derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-20 | -$28.20M derived: sum of 2 quarters · filed 2025-03-20 | -$48.81M derived: sum of 3 quarters · filed 2025-03-20 | -$67.52M 10-K · filed 2025-03-20 | ||||
| 2023-09-30 | -$17.98M 10-Q · filed 2024-11-13 | -$38.58M derived: sum of 2 quarters · filed 2024-11-13 | -$57.29M 10-Q · filed 2024-11-13 | -$72.74M derived: sum of 4 quarters · filed 2024-11-13 | ||||
| 2023-06-30 | -$20.60M 10-Q · filed 2024-08-06 | -$39.32M 10-Q · filed 2024-08-06 | -$54.76M derived: sum of 3 quarters · filed 2024-08-06 | -$61.39M derived: sum of 4 quarters · filed 2024-08-06 | ||||
| 2023-03-31 | -$18.71M 10-Q · filed 2024-05-09 | -$34.16M derived: sum of 2 quarters · filed 2024-05-09 | -$40.79M derived: sum of 3 quarters · filed 2024-05-09 | -$47.13M derived: sum of 4 quarters · filed 2024-05-09 | ||||
| 2022-12-31 | -$15.44M derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-21 | -$22.07M derived: sum of 2 quarters · filed 2024-03-21 | -$28.42M derived: sum of 3 quarters · filed 2024-03-21 | -$35.52M 10-K · filed 2024-03-21 | ||||
| 2022-09-30 | -$6.63M 10-Q · filed 2023-11-09 | -$18.94M 10-Q · filed 2022-11-02 | -$12.97M derived: sum of 2 quarters · filed 2023-11-09 | -$20.07M 10-Q · filed 2023-11-09 | -$63.44M 10-Q · filed 2022-11-02 | $26.55M derived: sum of 4 quarters · filed 2023-11-09 | ||
| 2022-06-30 | -$6.34M 10-Q · filed 2023-08-10 | -$19.80M 10-Q · filed 2022-08-11 | -$13.44M 10-Q · filed 2023-08-10 | -$44.50M 10-Q · filed 2022-08-11 | $33.18M derived: sum of 3 quarters · filed 2023-08-10 | $10.50M derived: sum of 4 quarters · filed 2023-08-10 | ||
| 2022-03-31 | -$7.10M 10-Q · filed 2023-05-15 | -$24.70M 10-Q · filed 2022-05-12 | $39.52M derived: sum of 2 quarters · filed 2023-05-15 | $16.84M derived: sum of 3 quarters · filed 2023-05-15 | -$7.67M derived: sum of 4 quarters · filed 2023-05-15 | |||
| 2021-12-31 | $46.62M derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-23 | $23.94M derived: sum of 2 quarters · filed 2023-03-23 | -$569.00K derived: sum of 3 quarters · filed 2023-03-23 | -$19.45M 10-K · filed 2023-03-23 | -$89.58M 10-K · filed 2022-03-31 | |||
| 2021-09-30 | -$22.68M 10-Q · filed 2022-11-02 | -$47.19M derived: sum of 2 quarters · filed 2022-11-02 | -$66.08M 10-Q · filed 2022-11-02 | -$79.18M derived: sum of 4 quarters · filed 2022-11-02 | ||||
| 2021-06-30 | -$24.51M 10-Q · filed 2022-08-11 | -$43.40M 10-Q · filed 2022-08-11 | -$56.50M derived: sum of 3 quarters · filed 2022-08-11 | -$64.61M derived: sum of 4 quarters · filed 2022-08-11 | ||||
| 2021-03-31 | -$18.89M 10-Q · filed 2022-05-12 | -$31.99M derived: sum of 2 quarters · filed 2022-05-12 | -$40.10M derived: sum of 3 quarters · filed 2022-05-12 | -$46.56M derived: sum of 4 quarters · filed 2022-05-12 | ||||
| 2020-12-31 | -$13.10M derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-31 | -$21.21M derived: sum of 2 quarters · filed 2022-03-31 | -$27.68M derived: sum of 3 quarters · filed 2022-03-31 | -$32.92M 10-K · filed 2022-03-31 | ||||
| 2020-09-30 | -$8.11M 10-Q · filed 2021-11-10 | -$14.57M derived: sum of 2 quarters · filed 2021-11-10 | -$19.82M 10-Q · filed 2021-11-10 | |||||
| 2020-06-30 | -$6.46M 10-Q · filed 2021-08-12 | -$11.71M 10-Q · filed 2021-08-12 | ||||||
| 2020-03-31 | -$5.24M 10-Q · filed 2021-05-13 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Atea Pharmaceuticals, Inc. (AVIR) | United States | $0.414B | -2.26 |
| RELMADA THERAPEUTICS, INC. (RLMD) | United States | $0.406B | -11.92 |
| Opus Genetics, Inc. (IRD) | United States | $0.406B | -3.16 |
| DiaMedica Therapeutics Inc. (DMAC) | United States | $0.423B | -10.11 |
| Arcturus Therapeutics Holdings Inc. (ARCT) | $0.402B | -2.05 | |
| GALECTIN THERAPEUTICS INC (GALT) | United States | $0.399B | -11.06 |
| PROTHENA CORP PUBLIC LTD CO (PRTA) | Ireland | $0.428B | -11.53 |
| Turn Therapeutics Inc. (TTRX) | United States | $0.397B | -25.68 |
| CYPHERPUNK TECHNOLOGIES INC. (CYPH) | United States | $0.438B | -75.63 |
| Quoin Pharmaceuticals Ltd. (QNRX) | $0.443B | -17.85 |